In the past three years, prostate-specific membrane antigen (PSMA) has become a well-established target for imaging and therapy in prostate cancer, and the isotopes 43Sc and 47Sc have been explored for their potential in PSMA-targeted radioligand therapy [52,108]. The gene discussed is FOLH1; the disease is Familial prostate cancer.